The Application of Bortezomib in Treatment of Acute Leukemia

XU Pan^1,2, CHANG Linlin^1,2, ZHANG Shizhong^1,2, ZHU Honghu^1,3*

(¹Medical College of China Three Gorges University, Yichang 443000, China; ²Third-Grade Pharmacological Laboratory on Traditional Chinese Medicine, China Three Gorges University, Yichang 443000, China; ³The Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China)

Abstract:

Bortezomib is the first protease-targeted drug approved by the FDA, and it has significant effects in the treatment of multiple myeloma and mantle cell lymphoma. The relevant mechanism for bortezomib may become a potential treatment for acute leukemia in recent years. There is evidence that bortezomib can benefit patients when used in combination with other therapies. Clinical applications are primarily focused on the treatment of newly dignosed and relapse/refractory acute myeloid leukemia as well as acute lymphoblastic leukemia. This findings summarize the basic mechanisms and current clinical development of bortezomib.

CSTR: 32200.14.cjcb.2023.05.0015